Reiner Laus
Fondateur chez TRIO Pharmaceuticals, Inc.
Profil
Reiner Laus founded TRIO Pharmaceuticals, Inc., where he worked as Director.
Dr. Laus also currently works at Annias Immunotherapeutics, Inc., as President & Chief Executive Officer and CG Therapeutics, Inc., as Director.
Dr. Laus also formerly worked at Bavarian Nordic, Inc., as Chief Executive Officer, Bolt Biotherapeutics, Inc., as President & Chief Executive Officer, Dendreon Corp., as Vice President-Research & Development, and Bavarian Nordic A, as President-Cancer Vaccines Division & EVP from 2012 to 2013.
Dr. Laus received his doctorate degree from Stanford University and doctorate degree from the University of Kiel.
Postes actifs de Reiner Laus
| Sociétés | Poste | Début |
|---|---|---|
| CG Therapeutics, Inc. | Directeur/Membre du Conseil | 03/03/2011 |
Annias Immunotherapeutics, Inc.
 Annias Immunotherapeutics, Inc. BiotechnologyHealth Technology Annias Immunotherapeutics, Inc. operates as an clinical stage company. It develops and sells therapeutic vaccine for the treatment of malignant brain tumor. The company is headquartered in Saratoga, CA. | Directeur Général | - |
TRIO Pharmaceuticals, Inc.
 TRIO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TRIO Pharmaceuticals, Inc. is a privately held cancer therapeutics company based in QB3. Triobody™ and TDC™ can synergize with current cancer drugs to improve efficacy. The American company is pioneering dual action drugs to generate immunogenic tumors. The company's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded by Reiner Laus and is developing first-in-class dual action antibody drug conjugates, Triobody Drug Conjugate (TDC™), and dual action antibody drugs, Triobody™, that stop both tumor growth and immunosuppression with and without payload delivery, respectively. | Fondateur | - |
Anciens postes connus de Reiner Laus
| Sociétés | Poste | Fin |
|---|---|---|
| BAVARIAN NORDIC A/S | Corporate Officer/Principal | 24/01/2013 |
| BOLT BIOTHERAPEUTICS, INC. | Directeur Général | - |
Bavarian Nordic, Inc.
 Bavarian Nordic, Inc. Miscellaneous Commercial ServicesCommercial Services Bavarian Nordic, Inc. engages in researching and manufacturing drugs to treat cancer. The company is headquartered in Morrisville, NC. | Directeur Général | - |
| DENDREON CORPORATION | Directeur Technique/Scientifique/R&D | - |
Formation de Reiner Laus
| Stanford University | Doctorate Degree |
| University of Kiel | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAVARIAN NORDIC A/S | Health Technology |
| BOLT BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Bavarian Nordic, Inc.
Bavarian Nordic, Inc. Miscellaneous Commercial ServicesCommercial Services Bavarian Nordic, Inc. engages in researching and manufacturing drugs to treat cancer. The company is headquartered in Morrisville, NC. | Commercial Services |
| CG Therapeutics, Inc. | |
Annias Immunotherapeutics, Inc.
Annias Immunotherapeutics, Inc. BiotechnologyHealth Technology Annias Immunotherapeutics, Inc. operates as an clinical stage company. It develops and sells therapeutic vaccine for the treatment of malignant brain tumor. The company is headquartered in Saratoga, CA. | Health Technology |
TRIO Pharmaceuticals, Inc.
TRIO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TRIO Pharmaceuticals, Inc. is a privately held cancer therapeutics company based in QB3. Triobody™ and TDC™ can synergize with current cancer drugs to improve efficacy. The American company is pioneering dual action drugs to generate immunogenic tumors. The company's innovative antibody drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded by Reiner Laus and is developing first-in-class dual action antibody drug conjugates, Triobody Drug Conjugate (TDC™), and dual action antibody drugs, Triobody™, that stop both tumor growth and immunosuppression with and without payload delivery, respectively. | Health Technology |
